The quality and accessibility of the active pharmaceutical ingredients (APIs) that drive these drugs are important due to the growing global demand for effective treatments for major depressive disorder (MDD). As a multimodal antidepressant, vortioxetine API is at the top of this therapeutic class. To guarantee the creation of pharmaceutical products that are safe, effective, and compliant, pharmaceutical engineers and procurement specialists must comprehend the complex details of this molecule. From its chemical identity to supply chain considerations, this guide explores the important technical aspects of vortioxetine API.
Vortioxetine API chemical make-up and characteristics
The basis for effective formulation and regulatory compliance is a thorough comprehension of the chemical identity of vortioxetine API. 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine is the chemical name for this compound. Manufacturers frequently sell it as vortioxetine hydrobromide, a hydrobromide salt. Technical documentation often lists Lu-AA21004 as a synonym.
The hydrobromide salt has the molecular formula C₄₆H₂₃BrN₂S. This translates to a molecular weight of roughly 379.36 g/mol. The molecular weight of the free base is 298.45 g/mol. The CAS number is necessary for accurate identification. The hydrobromide salt normally has the CAS number 960203-27-4, whereas the free base has 508233-74-7.
Vortioxetine API is a crystalline powder that is white to off-white. Formulators’ handling of the material is determined by its physicochemical characteristics. pH affects the solubility profile. It is only slightly soluble in water, but it dissolves easily in organic solvents like ethanol and methanol. Another important factor is polymorphism. There are various polymorphic forms of the API. To consistently produce the stable polymorph, manufacturers must regulate crystallization. This stability guarantees consistent drug performance. The material also has particular melting points and hygroscopic characteristics that affect processing and storage conditions. It is a serotonin modulator and stimulator in terms of pharmacology.
Vortioxetine’s pharmacology and mechanism of action in relation to API level
The intrinsic pharmacological mechanism of the vortioxetine API directly affects the final drug product’s efficacy. Vortioxetine has a multimodal mode of action, in contrast to conventional selective serotonin reuptake inhibitors (SSRIs). This distinct profile combines modulation of multiple serotonin receptor subtypes with inhibition of the serotonin transporter (SERT).
In particular, the API inhibits the 5-HT3, 5-HT7, and 5-HT1D receptors. It acts as a full agonist at the 5-HT1A receptor and as a partial agonist at the 5-HT1B receptor. Its intricate receptor profile sets it apart from other antidepressants.
When designing drugs, pharmaceutical scientists need to take these interactions into account. The molecule’s multimodal action suggests that it affects neurotransmission via several pathways at once. This wider range of activities seeks to elevate mood and possibly alleviate depression-related cognitive symptoms. Maintaining this delicate receptor binding profile requires the API manufacturer to protect the molecule’s chemical integrity. These particular interactions could be changed by any impurity or degradation.
Vortioxetine HBr API quality standards and pharmaceutical-grade specifications
Strict adherence to defined quality standards is necessary when sourcing vortioxetine API pharmaceutical grade. There are strict requirements for purity. According to High-Performance Liquid Chromatography (HPLC), high-purity API normally requires a purity level of ≥ 99.5%. Major pharmacopoeias such as the European Pharmacopoeia (EP) and the United States Pharmacopeia (USP) have requirements that this standard complies with.
Permissible impurity levels are governed by specific specifications. There are specific limits for both known and unknown impurities, and overall impurities must typically stay below 0.5%. Additionally, manufacturers closely monitor heavy metals. Lead (Pb) content, for example, typically needs to be kept below 10 or 20 parts per million. Another issue is residual solvents from the synthesis process. Suppliers are required to test these solvents to make sure they adhere to International Council for Harmonization (ICH) regulations.
Bioavailability and dissolution rates are impacted by particle size distribution (PSD). Depending on the final formulation strategy, a typical specification might call for a D90 value of ≤ 100 µm. Another important factor is moisture content or drying loss. When producing dosage forms, too much moisture can deteriorate the API or alter its weight accuracy.
Good Manufacturing Practices (GMP) are included in compliance. Every facility that has received GMP certification for vortioxetine API operates under strict quality control procedures. Stability studies determine storage conditions. Suppliers generally advise storing the crystalline powder at controlled room temperatures in tightly sealed containers protected from light and moisture.
Overview of the manufacturing and synthesis route
Producing vortioxetine hydrobromide requires a multi-step organic synthesis. This intricate process creates the sophisticated API from basic chemical starting materials. Chemical engineers design these pathways to minimize contaminants and increase yield.
Coupling reactions are a typical synthesis pathway. Manufacturers may, for instance, react a derivative of piperazine with a particular substituted phenyl sulfide. Temperature, pressure, and catalysts must all be precisely controlled for the reaction conditions. The crude material is purified after the primary synthesis. Here, recrystallization is the standard procedure. Byproducts and unreacted starting materials are eliminated in this step.
Importantly, recrystallization controls the polymorphic form. As mentioned earlier, polymorphism affects stability and solubility. Therefore, the manufacturing process must consistently produce the intended stable crystal structure. Manufacturers often follow crystallization with milling. This mechanical method modifies the particle size to satisfy particular specifications for the manufacturing of tablets or capsules.
Manufacturing APIs on a large scale presents new difficulties. Reaction kinetics can change when a process is scaled up. To ensure consistency from batch to batch, engineers must modify the parameters. Every aspect of this procedure is recorded in regulatory documentation, such as the Drug Master File (DMF) or Certificate of Analysis (COA). Regulatory agencies can see from these documents that the procedure is reliable and repeatable.
In pharmaceutical formulations and research, vortioxetine API applications
The production of antidepressant formulations is the primary use of vortioxetine API. It is the active component of many newly available generic versions as well as branded drugs like Trintellix (formerly Brintellix). The API is usually processed by formulators to create immediate-release tablets.
The API is necessary for research and development in addition to commercial production. Bulk API is used by contract manufacturers and research labs to explore novel therapeutic indications. It is an intriguing option for research involving other disorders of the central nervous system (CNS) due to its distinct multimodal mechanism.
Extended-release versions or other dosage forms, such as oral solutions, may be possible due to its physicochemical characteristics. These developments may provide better pharmacokinetic profiles or increase patient compliance. The availability of premium vortioxetine API active ingredients supports these research initiatives.
Vortioxetine API: Sourcing, Supply Chain, and Market
When sourcing bulk supplies of vortioxetine API, procurement teams must navigate a challenging environment. With a notable concentration in Asia and Europe, the market includes manufacturers and suppliers of vortioxetine API worldwide. Examining a partner’s quality systems and regulatory history is necessary to choosing the best one.
The selection process is based on GMP compliance. To confirm their claims, pharmaceutical companies must audit possible exporters of vortioxetine API. Vortioxetine’s market is still expanding. The rising incidence of mental health conditions drives the need for efficient antidepressants. As a result, this API is becoming more widely used globally.
There are risks in the supply chain. Shortages may result from the concentration of necessary starting materials in particular areas. A barrier to entry is also created by the synthesis’s technical complexity. Failures in quality control at the supplier level have the potential to cause supply chain disruptions. Therefore, it is important for risk mitigation to keep up relationships with dependable suppliers who provide transparent impurity profiling and consistent quality.
Regulatory, compliance, and quality-assurance factors for the use of vortioxetine API
Every facet of using vortioxetine API is governed by regulatory compliance. Without the proper documentation, pharmaceutical companies cannot use an API to produce commercial drugs. The most important document is the Drug Master File (DMF). It contains private, in-depth details on how manufacturers make, process, package, and store the API.
Each batch needs to have a Certificate of Analysis (COA) in addition to the DMF. This document attests to the fact that the particular batch satisfies all established requirements. Material Safety Data Sheets (MSDS) ensure safe handling at the facility. For major markets, manufacturers must strictly adhere to pharmacopeial standards such as USP, EP, JP, and CP.
Quality assurance teams must independently test these documents. To find any unexpected compounds, they perform impurity profiling. Toxic solvents are either absent or within safe bounds. Patient safety is safeguarded by heavy metal testing. Stability studies offer information about the API’s behavior over time. Any quality problem can be traced back to the original raw materials thanks to batch traceability.
Businesses must comply with local laws when importing APIs. Regulatory bodies in the US (FDA), Europe (EMA), and other jurisdictions require specific filings and inspections. The accuracy and completeness of the technical information supplied by the API manufacturer are necessary for successful registration.
An overview of the vortioxetine API’s key specification table
When assessing vortioxetine API, engineers and procurement officers should confirm the necessary specifications listed in the following table.
|
Parameter |
Specification / Typical Value / Notes |
|
Synonyms / INN |
Vortioxetine, vortioxetine HBr, Lu-AA21004 |
|
CAS No. |
508233-74-7 (Free Base); 960203-27-4 (HBr Salt) |
|
Molecular Formula |
C₁₈H₂₃BrN₂S (HBr Salt) |
|
Molecular Weight |
~ 379.36 g/mol (as HBr salt) |
|
Physical State |
White to off-white crystalline powder |
|
Purity (HPLC) |
≥ 99.5% (Pharmaceutical Grade) |
|
Impurities (Total) |
≤ 0.5% |
|
Heavy Metals (Pb) |
≤ 10 ppm (or as per specific regulation) |
|
Particle Size (D90) |
≤ 100 µm (Typical, customizable) |
|
Solubility |
Soluble in methanol/ethanol; slightly soluble in water |
|
Polymorphism |
Stable polymorph required (Controlled crystallization) |
|
Storage Conditions |
Protected from light and moisture; controlled room temperature |
Typical Questions & Brief Responses
What is the vortioxetine API’s CAS number?
Vortioxetine free base’s CAS number is 508233-74-7. The CAS number 960203-27-4 is commonly used for the hydrobromide salt form.
How much purity is usually required for vortioxetine HBr API of pharmaceutical grade?
A purity of at least 99.5% by HPLC is typically required for pharmaceutical-grade vortioxetine HBr API. To meet USP/EP standards, it must also adhere to stringent limits for heavy metals and impurities.
What is the formula and molecular weight of vortioxetine HBr API?
Vortioxetine hydrobromide has the molecular formula C₁⋅H₂₃BrN₂S. It has a molecular weight of about 379.36 g/mol.
For what therapeutic purpose is vortioxetine API designed?
For the treatment of major depressive disorder (MDD), manufacturers use vortioxetine API to create antidepressants. It can be found in generic versions as well as brands like Trintellix and Brintellix.
How does vortioxetine work pharmacologically?
Serotonin reuptake is inhibited by vortioxetine (SERT inhibition). It also has a multimodal antidepressant effect by modulating several serotonin receptors.
